Pinealon / PE22-28 / Selank
This combination pairs Pinealon (a pineal-derived tripeptide studied in Russian gerontology research), PE22-28 (a neuroprotective research peptide), and Selank (studied for anxiolytic effects) — three compounds targeting brain health from different angles.
- Combines three peptides studied in neurological research
- Selank studied for anxiolytic effects in Russian trials
- Explored for cognitive and neuroprotective support
No commitment · Cancel anytime · Physician evaluation required
About Pinealon / PE22-28 / Selank
Pinealon is a synthetic tripeptide from the same Russian bioregulator research tradition as Epithalon, studied in preclinical models for neuroprotective and pineal-regulatory effects. PE22-28 is a newer, less-studied peptide fragment researched for neuroprotection. Selank, an ACTH-derived heptapeptide developed in Russia, has been studied for anxiolytic and antiasthenic (anti-fatigue) effects, including trials for generalized anxiety and neurasthenia.
What the research shows — and its limits
Across all three compounds, the evidence base is concentrated in Russian and Eastern European research institutions, with most human data not independently replicated in Western randomized controlled trials. Selank has the most developed human research of the three, including small trials for anxiety-related conditions. Pinealon and PE22-28 have considerably thinner published human data, consisting mostly of preclinical and mechanistic research.
Who it's for
This combination is generally considered by adults interested in cognitive and stress-resilience support as part of a broader wellness program, understanding this is an area where independent, large-scale human trials are still limited.
How It's Administered
These peptides are typically administered via subcutaneous injection or intranasal delivery depending on the specific compound. Your physician will determine an appropriate protocol during your evaluation.
Safety & Considerations
Available safety data for all three compounds, drawn mostly from smaller studies and preclinical research, has not identified significant safety concerns at studied doses, but none has the large-scale controlled human safety trial base of an FDA-approved medication.
Your physician will review your health history during your evaluation. Not all applicants will qualify.
Selected References
The following peer-reviewed sources informed the summary above. Evidence quality varies — some reflect large controlled human trials, others early-stage or animal research, as noted.
- Compare Semax, Selank & DSIP — evidence base and regional research concentration summary
NewGen Peptides research guide, 2026